Takeda

DFA104 is a combination therapy program pairing pramlintide with metreleptin, sponsored by Takeda for the treatment of obesity. The program reached Phase 2 clinical development but was terminated, with the latest milestone recorded on 15 April 2015. Metreleptin, the leptin analogue component, is administered by injection and has achieved regulatory approval in multiple markets: the European Union (approved 3 November 2025 by EMA under the brand name MYALEPTA, marketed by Chiesi Farmaceutici), Japan (approved March 2013), and the United States (BLA 125390). The combination approach reflects a strategy to address obesity through dual mechanisms targeting metabolic regulation. However, the termination of DFA104 indicates that Takeda discontinued development of this particular combination, though metreleptin itself remains an approved therapeutic option for specific patient populations with lipodystrophy and related metabolic disorders. The program's discontinuation suggests either efficacy, safety, or commercial considerations led to the decision to halt further advancement.

Obesity represents a significant unmet medical need with limited pharmacological treatment options, particularly for patients with genetic or acquired forms of lipodystrophy where leptin signalling is impaired. Metreleptin addresses a specific subset of obesity patients—those with congenital or acquired lipodystrophy—by replacing deficient leptin and restoring metabolic homeostasis. The combination of pramlintide (an amylin analogue) with metreleptin was theoretically designed to provide complementary metabolic benefits through distinct pathways: pramlintide promotes satiety and slows gastric emptying, while metreleptin restores leptin signalling. The commercial significance lies in the obesity market's substantial size and the scarcity of approved pharmacotherapies with robust efficacy and tolerability profiles. However, the termination of DFA104 suggests that the combination did not meet commercial or clinical viability thresholds. Metreleptin's approval in the EU, Japan, and US indicates regulatory recognition of its therapeutic value, though its use remains restricted to lipodystrophy indications rather than general obesity. The competitive landscape includes other metabolic and endocrine therapies, though many listed competitors (MEPSEVII, PALYNZIQ, ELAPRASE, VIMIZIM, NAGLAZYME, BRINEURA) address rare genetic metabolic disorders rather than obesity directly.

Drug Class: Combination of amylin analogue (pramlintide) and leptin analogue (metreleptin).

Modality: Small molecule (pramlintide component); protein/recombinant peptide (metreleptin component).

Route of Administration: Metreleptin is administered by subcutaneous injection; pramlintide route not specified in available data.

Therapeutic Classification: Alimentary tract and metabolism (ATC A16).

Mechanism of Action: Not disclosed for the combination program. Metreleptin functions as a leptin receptor agonist, restoring leptin signalling in patients with leptin deficiency. Pramlintide is an amylin analogue that modulates appetite and gastric motility.

Target: Not disclosed.

Related Therapies: Metreleptin (MYALEPTA) is approved as monotherapy for lipodystrophy; pramlintide (SYMLIN) is approved for diabetes management. Other obesity-related pharmacotherapies exist but are not detailed in the provided competitive set.

First Approval: Metreleptin achieved FDA approval, EMA approval (3 November 2025), and PMDA approval (March 2013). DFA104 as a combination program did not advance to approval.

United States (FDA): Metreleptin approved under BLA 125390; sponsor listed as Chiesi Farmaceutici SPA. DFA104 combination program did not advance to FDA submission.

European Union (EMA): Metreleptin (MYALEPTA) approved 3 November 2025 under EMEA/H/C/004218; Marketing Authorisation Holder: Chiesi Farmaceutici S.p.A. DFA104 combination program did not advance to EMA submission.

Japan (PMDA): Metreleptin approved March 2013. DFA104 combination program regulatory status in Japan not disclosed.

China (NMPA): Regulatory status not yet disclosed.

Program Status: DFA104 was terminated at Phase 2; no regulatory filings for the combination program are documented. Metreleptin as a monotherapy remains the approved component, restricted to lipodystrophy indications.

Strategic Implications: Takeda's termination of DFA104 at Phase 2 suggests the combination of pramlintide and metreleptin did not meet efficacy, safety, or commercial viability thresholds. The decision to discontinue reflects a strategic pivot away from this particular obesity approach, despite metreleptin's subsequent approval in multiple markets as a monotherapy for lipodystrophy.

Competitive Implications: The obesity pharmacotherapy market remains underserved, with limited approved options. Metreleptin's approval is restricted to lipodystrophy rather than general obesity, limiting its market penetration. The termination of DFA104 removes one potential combination strategy from the competitive landscape, leaving room for alternative approaches from other sponsors.

Future Catalysts: No further development milestones are anticipated for DFA104. Metreleptin's ongoing commercial performance in approved indications (lipodystrophy) may inform future obesity research strategies, though the combination approach with pramlintide has been abandoned.

Expected Milestones: None anticipated for DFA104. The program is terminated and unlikely to be revived based on available evidence.